NCT05882604

MESNA Injection for TMJ Internal Derangement

Treatment of Temporomandibular Joint Internal Derangement Using MESNA Injection

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The pathogenesis of temporomandibular disorders focusing on the biochemistry of the synovial fluid in various stages of temporomandibular joint disease. The role of inflammation has been investigated and proposed as an underlying mechanism of pain and dysfunction of temporomandibular joint. MESNA (sodium 2-mercaptoethanesulfonate) was approved several years ago and marketed in several formulations as a mucolytic agent in the respiratory field, since it breaks the disulfide bonds between polypeptide chains of mucus. The tissue distribution of MESNA is negligible, and the elimination of the substance is rapidly and completely achieved by kidney

Detailed description

Clarification (July 2025): Recruitment was completed in March 2023 following clinical scheduling and preliminary departmental clearance, while formal written ethical approval was finalized in early April 2023. All patients were followed up for one year, and the study was completed by March 2024.

Conditions

• TMJ Disorder

Interventions

Type	Name	Description
DRUG	Mesna Injection	1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.
DRUG	Arthrocentesis with ringer solution	Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid

Timeline

• Start date: 2023-03-01
• Primary completion: 2024-03-10
• Completion: 2024-03-10
• First posted: 2023-05-31
• Last updated: 2025-07-24

Locations

1 site across 1 country: Egypt